Therapeutic targeting of the oncostatin M receptor-β prevents inflammatory heart failure

Basic Research in Cardiology

Volumn 109, Issue 1, 2014, Pages

  Pöling, Jochen ^a,b   Gajawada, Praveen ^a   Richter, Manfred ^c   Lörchner, Holger ^a   Polyakova, Victoria ^a,c   Kostin, Sawa ^a   Shin, Jaeyoung ^a   Boettger, Thomas ^a   Walther, Thomas ^c   Rees, Wolfgang ^b   Wietelmann, Astrid ^a   Warnecke, Henning ^b,d   Kubin, Thomas ^a   Braun, Thomas ^a  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b Schuchtermann Klinik   (Germany)

^c KERCKHOFF HEART CENTER   (Germany)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Cell survival program; Cytokine; Dedifferentiation; Dilative cardiomyopathy; Insulin growth factor 1 (IGF 1); Myoglobin

Indexed keywords

ACTIN; ACTININ; ATRIAL NATRIURETIC FACTOR; B RAF KINASE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; MYOGLOBIN; NEUTRALIZING ANTIBODY; ONCOSTATIN M; ONCOSTATIN M RECEPTOR BETA; ONCOSTATIN M RECEPTOR BETA ANTIBODY; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEDIFFERENTIATION; CELL INFILTRATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE MODEL; DRUG TARGETING; GENE; GENE INACTIVATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE CELL; HEART OUTPUT; HEART PERFORMANCE; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; INHIBITION KINETICS; MOUSE; NONHUMAN; ONCOSTATIN M RECEPTOR BETA GENE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, NEUTRALIZING; BLOTTING, WESTERN; CARDIOMYOPATHY, DILATED; CELL DEDIFFERENTIATION; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; INFLAMMATION; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MYOCYTES, CARDIAC; ONCOSTATIN M RECEPTOR BETA SUBUNIT; SIGNAL TRANSDUCTION;

EID: 84888238299     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-013-0396-3     Document Type: Article

References (29)

1. Aasland D, Schuster B, Grotzinger J, Rose-John S, Kallen KJ (2003) Analysis of the leukemia inhibitory factor receptor functional domains by chimeric receptors and cytokines. Biochemistry 42:5244-5252. doi: 10.1021/bi0263311 (Pubitemid 36560420)
2. Ahmad S, Rai TS, Khullar M, Bahl A, Saikia UN, Thungapathra M, Kumar RM, Mahajan R, Talwar KK (2010) Decreased myocardial expression of dystrophin and titin mRNA and protein in dilated cardiomyopathy: possibly an adverse effect of TNF-alpha. J Clin Immunol 30:520-530. doi: 10.1007/s10875-010-9388-3
3. Ahmed ST, Ivashkiv LB (2000) Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J Immunol 165:5227-5237
4. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R (2008) The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 120:172-185. doi: 10.1016/j.pharmthera.2008.08.002
5. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Lohr KN (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124-134 (Pubitemid 351651555)
6. Feldmann M, Maini SR (2008) Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 223:7-19. doi: 10.1111/j.1600-065X.2008.00626.x (Pubitemid 351986171)
7. Fischer P, Hilfiker-Kleiner D (2007) Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol 102:279-297 (Pubitemid 46909707)
8. Fourcin M, Chevalier S, Lebrun JJ, Kelly P, Pouplard A, Wijdenes J, Gascan H (1994) Involvement of gp130/interleukin-6 receptor transducing component in interleukin-11 receptor. Eur J Immunol 24:277-280. doi: 10.1002/eji.1830240143 (Pubitemid 24014711)
9. Frangogiannis NG (2012) Regulation of the inflammatory response in cardiac repair. Circ Res 110:159-173. doi: 10.1161/CIRCRESAHA.111.243162
10. Gordon JW, Shaw JA, Kirshenbaum LA (2011) Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res 108:1122-1132. doi: 10.1161/CIRCRESAHA.110.226928
11. Hein S, Block T, Zimmermann R, Kostin S, Scheffold T, Kubin T, Klovekorn WP, Schaper J (2009) Deposition of nonsarcomeric alpha-actinin in cardiomyocytes from patients with dilated cardiomyopathy or chronic pressure overload. Exp Clin Cardiol 14:e68-e75
12. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1-20. doi: 10.1042/BJ20030407 (Pubitemid 37046923)
13. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand J-L, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B, Schultheiss H-P, Tschope C, Van Bilsen M, Zannad F, McMurray J, Shah AM (2009) Inflammation as a therapeutic target in heart failure? A scientific statement from the translational research committee of the heart failure association of the European society of cardiology. Eur J Heart Fail 11:119-129. doi: 10.1093/eurjhf/hfn043
14. Hintzen C, Quaiser S, Pap T, Heinrich PC, Hermanns HM (2009) Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Arthr Rheum 60:1932-1943. doi: 10.1002/art.24602
15. Kamimura D, Ishihara K, Hirano T (2003) IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149:1-38. doi: 10.1007/s10254-003-0012-2
16. Kaye DM, Krum H (2007) Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov 6:127-139 (Pubitemid 46758752)
17. Kleinbongard P, Heusch G, Schulz R (2010) TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 127:295-314. doi: 10.1016/j.pharmthera.2010.05.002
18. Kolattukudy PE, Quach T, Bergese S, Breckenridge S, Hensley J, Altschuld R, Gordillo G, Klenotic S, Orosz C, Parker-Thornburg J (1998) Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am J Pathol 152:101-111 (Pubitemid 28028051)
19. Kubin T, Poling J, Kostin S, Gajawada P, Hein S, Rees W, Wietelmann A, Tanaka M, Lorchner H, Schimanski S, Szibor M, Warnecke H, Braun T (2011) Oncostatin m is a major mediator of cardiomyocyte dedifferentiation and remodeling. Cell Stem Cell 9:420-432 pii: S1934-5909(11)00394-8
20. Kubin T, Tomars M, Fach C, Hein S, Bramlage P, Shim GJ, Scholz D, Kostin S, Zimmermann R, Elsasser A, Schaper W, Schaper J (2005) Transforming growth factor-beta1 downregulates beating frequency and remodeling of cultured rat adult cardiomyocytes. Cell Tissue Res 321:57-66 (Pubitemid 40984839)
21. Maier HJ, Schips TG, Wietelmann A, Kruger M, Brunner C, Sauter M, Klingel K, Bottger T, Braun T, Wirth T (2012) Cardiomyocyte-specific I kappa B kinase (IKK)/NF-kappa B activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci USA 109:11794-11799. doi: 10.1073/pnas. 1116584109
22. Packer M (1995) Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J 16(Suppl F):4-6
23. Person V, Kostin S, Suzuki K, Labeit S, Schaper J (2000) Antisense oligonucleotide experiments elucidate the essential role of titin in sarcomerogenesis in adult rat cardiomyocytes in long-term culture. J Cell Sci 113(Pt 21):3851-3859
24. Poling J, Gajawada P, Lorchner H, Polyakowa V, Szibor M, Bottger T, Warnecke H, Kubin T, Braun T (2012) The Janus face of OSM mediated cardiomyocyte dedifferentiation during cardiac repair and disease. Cell Cycle 11. pii:19024
25. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL (1996) Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2:243-249
26. Tanaka M, Hirabayashi Y, Sekiguchi T, Inoue T, Katsuki M, Miyajima A (2003) Targeted disruption of oncostatin M receptor results in altered hematopoiesis. Blood 102:3154-3162. doi: 10.1182/blood-2003-02-0367 (Pubitemid 37314751)
27. Weiss TW, Speidl WS, Kaun C, Rega G, Springer C, Macfelda K, Losert UM, Grant SL, Marro ML, Rhodes AD, Fuernkranz A, Bialy J, Ullrich R, Holzmann P, Pacher R, Maurer G, Huber K, Wojta J (2003) Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. Cardiovasc Res 59:628-638 (Pubitemid 38368679)
28. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, Tanaka K, Wang WZ, Mori C, Shiota K, Yoshida N, Kishimoto T (1996) Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 93:407-411 (Pubitemid 26041485)
29. Yoshimura A, Arai K (1996) Physician education: the erythropoietin receptor and signal transduction. Oncologist 1:337-339